Search Result

Results for "

DP receptor

" in MedChemExpress (MCE) Product Catalog:

標的別:	Aldose Reductase (1) Amyloid-β (1) Antibody-Drug Conjugates (ADCs) (1) Cytochrome P450 (1) Drug Intermediate (1) Drug Isomer (1) EGFR (1) Endogenous Metabolite (4) Interleukin Related (2) Isotope-Labeled Compounds (3) nAChR (1) Neuropeptide FF Receptor (2) Opioid Receptor (2) PPAR (2) Prostaglandin Receptor (43) Reference Standards (3) Serotonin Transporter (1) Src (2) TNF Receptor (1) Vasopressin Receptor (1)
研究分野別:	Cancer (4) Cardiovascular Disease (8) Endocrinology (22) Inflammation/Immunology (27) Metabolic Disease (4) Neurological Disease (11)

標的別:

Aldose Reductase (1)

Amyloid-β (1)

Antibody-Drug Conjugates (ADCs) (1)

Cytochrome P450 (1)

Drug Intermediate (1)

Drug Isomer (1)

EGFR (1)

Endogenous Metabolite (4)

Interleukin Related (2)

Isotope-Labeled Compounds (3)

nAChR (1)

Neuropeptide FF Receptor (2)

Opioid Receptor (2)

PPAR (2)

Prostaglandin Receptor (43)

Reference Standards (3)

Serotonin Transporter (1)

Src (2)

TNF Receptor (1)

Vasopressin Receptor (1)

研究分野別:

Cancer (4)

Cardiovascular Disease (8)

Endocrinology (22)

Inflammation/Immunology (27)

Metabolic Disease (4)

Neurological Disease (11)

阻害剤およびアゴニスト

蛍光色素

ペプチド

天然物

同位体標識化合物

製品番号	製品名	Target	研究分野	構造式

HY-101987

BW 245C	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
BW 245C is a prostanoid DP-receptor (DP1) agonist, used to study stroke.

HY-16763

Asapiprant 1 Publications Verification S-555739	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Asapiprant is a potent and selective **DP₁ receptor antagonist with a K_i** of 0.44 nM.

HY-14973

Vidupiprant AMG 853	Prostaglandin Receptor	Inflammation/Immunology
Vidupiprant (AMG 853) is a phenylacetic acid derivative. Vidupiprant is a potent and orally active CRTH2 (DP2) and prostanoid D receptor (DP or DP1) dual antagonist with IC₅₀s of 3 nM and 4 nM in buffer, and 8 nM and 35 nM in human plasma, respectively. Vidupiprant has the potential for asthma treatment .

HY-16751

Ralinepag APD811	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC₅₀s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.

HY-16768

Fevipiprant 1 Publications Verification QAW039; NVP-QAW039	Prostaglandin Receptor	Cardiovascular Disease
Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an K_d value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma .

HY-50175

Laropiprant MK-0524	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Laropiprant is a potent and selective DP receptor antagonist with K_i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively .

HY-113366

Prostaglandin J2 PGJ2	Prostaglandin Receptor Endogenous Metabolite	Neurological Disease
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-10418

AH 6809 4 Publications Verification	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
AH 6809 is an antagonist of EP and DP receptor, with K_is of 1217, 1150, 1597, and 1415 nM for the cloned human EP₁, EP₂, EP₃-III, and DP receptor respectively. AH 6809 has a K_i of 350 nM for mouse EP₂ receptor .

HY-15342

Timapiprant 4 Publications Verification OC000459	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Timapiprant (OC000459) is a potent, selective, and orally active D prostanoid receptor 2 (DP₂, also known as CRTH2) antagonist. Timapiprant (OC000459) potently displaces [ ³H] PGD2 from human recombinant DP₂ (K_i=13 nM), rat recombinant DP₂ (K_i=3 nM), and human native DP₂ (K_i=4 nM). Timapiprant (OC000459) inhibits mast cell activation of Th2 lymphocytes and eosinophils .

HY-18971

TG4-155 1 Publications Verification	Prostaglandin Receptor	Neurological Disease Inflammation/Immunology Endocrinology Cancer
TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a K_i of 9.9 nM . TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1 . TG4-155 has an EP2 Schild K_B of 2.4 nM and displays 550-4750-fold selectivity for EP2 over EP1, EP3, EP4 and IP, but only 14-fold selectivity against the DP1 receptor .

HY-135783

AT 1001 1 Publications Verification	nAChR	Neurological Disease Metabolic Disease Inflammation/Immunology
AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a K_i value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease .

HY-15342A

Timapiprant sodium 4 Publications Verification OC000459 sodium	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP₂, also known as CRTH2) antagonist. Timapiprant sodium (OC000459 sodium) potently displaces [ ³H] PGD2 from human recombinant DP₂ (K_i=13 nM), rat recombinant DP₂ (K_i=3 nM), and human native DP₂ (K_i=4 nM). Timapiprant sodium (OC000459 sodium) inhibits mast cell activation of Th2 lymphocytes and eosinophils .

HY-136500

Prostaglandin H2 PGH2	Endogenous Metabolite Amyloid-β	Neurological Disease Inflammation/Immunology
Prostaglandin H2 (PGH2) is an endothelium-derived contracting factor. Prostaglandin H2 can cause vasoconstriction. Prostaglandin H2 is the common precursor of all PGs and is produced by several cells that express cyclooxygen-ases. Prostaglandin H2 can activate PGD2 receptors CRTH2 and DP via interacting directly with the receptors and/or by giving rise to PGD2 after catalytic conversion by plasma proteins. Prostaglandin H2 can induce eosinophils migration and inhibit platelet aggregation. Prostaglandin H2 can accelerate the formation of dimers and higher oligomers of amyloid β_1-42. Prostaglandin H2 can be used for the researches of inflammation and neurological disease, such as Alzheimer disease .

HY-13213

AM211 AM211 free acid	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
AM211 is a potent, selective and orally bioavailable prostaglandin D2 (PGD2) receptor type 2 (DP2) antagonist, with IC₅₀s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat DP2, respectively.

HY-114141

BI-671800	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells *(DP2/CRTH2), with IC₅₀* values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively . BI-671800 has potential for the treatment of poorly controlled asthma .

HY-118830

13,14-Dihydro-15-keto prostaglandin D2 DK-PGD2; 15-Oxo-13,14-dihydro-PGD2; 13,14-Dihydro-15-keto-PGD2	Prostaglandin Receptor	Endocrinology
13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the *DP2* receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .

HY-111271A

L 888607 Racemate	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
L 888607 Racemate is a selective prostaglandin D₂ receptor subtype 1 *(DP1)* antagonist, with K_is of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.

HY-125782

15(R)-15-Methyl prostaglandin D2 15(R)-15-Methyl PGD2	Prostaglandin Receptor	Metabolic Disease
15(R)-15-Methyl prostaglandin D2 (15(R)-15-methyl PGD2) is a metabolically stable synthetic analog of PGD2. The physiological actions of PGD2 include regulation of sleep, lowering of body temperature, inhibition of platelet aggregation and relaxation of vascular smooth muscle. PGD2 mediates its effects by 2 distinct G-protein-coupled receptors, DP1and CRTH2/DP2. 15(R)-15-Methyl prostaglandin D2 is a potent, selective agonist for the CRTH2/DP2 receptor. The EC₅₀ values for eosinophil CD11b expression, actin polymerization, and chemotaxis are 1.4, 3.8, and 1.7 nM, respectively, each of which is approximately 3-5 fold lower than those for PGD2. In contrast the EC₅₀ for the DP1-mediated increase in platelet cAMP by 15(R)-15-methyl PGD2 is >10 μM.

HY-13706

CAY10471 Racemate TM30089 Racemate	Prostaglandin Receptor	Endocrinology Cancer
CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective *prostaglandin D2 receptor* CRTH2 antagonist, with a K_i** of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (K_i, >10000 nM) or PGD2 receptor DP (K_i, 1200 nM). CAY10471 Racemate also has effect on mouse and rat orthologs of CRTH2 .

HY-118180

CAY10595	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
CAY10595 is a potent *CRTH2/DP2* receptor antagonist that binds to the human receptor with a K_i of 10 nM.

HY-P10395

DP50	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP50 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP50 can be used in analgesia-related research .

HY-P10394

DP32	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP32 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP32 can be used in analgesia-related research .

HY-172820

Trastuzumab envedotin DP303c	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

HY-122558

AM432 sodium	Prostaglandin Receptor	Neurological Disease
AM432 (sodium) is a potent and selective antagonist of the *DP₂* receptor (CRTH2). AM432 (sodium) exhibits excellent potency in a human whole blood eosinophil shape change assay with prolonged incubation. AM432 (sodium) also demonstrates excellent pharmacokinetics in dog and mouse models of inflammatory disease .

HY-50175A

Laropiprant sodium MK-0524 sodium	Prostaglandin Receptor	Inflammation/Immunology
Laropiprant sodium is a potent and selective DP receptor antagonist with K_i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively .

HY-114623

Prostaglandin D2 methyl ester	Prostaglandin Receptor	Inflammation/Immunology
Prostaglandin D2 methyl ester is a prodrug form of Prostaglandin D2 (HY-101988) that acts as a DP *receptor* inhibitor. can be used for research on allergic inflammations .

HY-19755

S-5751	Prostaglandin Receptor	Inflammation/Immunology
S-5751 is an orally active prostaglandin DP receptor antagonist. S-5751 inhibits cAMP generation in platelet-rich plasma induced by PGD2 with IC₅₀ 0.12 μM. S-5751 has anti-inflammatory activity. S-5751 can be used in asthma research .

HY-109186

Pexopiprant	Prostaglandin Receptor	Others
Pexopiprant is an oral antagonist of the prostaglandin D2 receptor 2 (DP2),K_i ＜ 100nM. Pexopiprant can be used in studies of asthma .

HY-U00423

CRTH2-IN-1 Ramatroban analog	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
CRTH2-IN-1 (Ramatroban analog) is a selective prostaglandin D2 receptor DP2 (CRTH2) antagonist with an IC₅₀ of 6 nM in a human DP2 binding assay.

HY-137308

15(R)-Prostaglandin D2 15R-PGD2	Prostaglandin Receptor	Inflammation/Immunology
15(R)-Prostaglandin D2 is a potential prostatic hormone DP(2) receptor (Prostaglandin Receptor) agonist with anti-inflammatory activity. 15(R)-Prostaglandin D2 increases actin polymerization in human eosinophils and increases cAMP levels in platelets .

HY-126911

11-keto Fluprostenol Fluprostenol Prostaglandin D2	Prostaglandin Receptor	Endocrinology
11-keto Fluprostenol is an analog of prostaglandin D2 (PGD2) with structural modifications intended to give it a prolonged half-life and greater potency. Fluprostenol is a well-studied, potent analog of PGF2α and acts primarily through the FP receptor. Oxidation at C-11 of fluprostenol yields 11-keto fluprostenol. 11-keto Fluprostenol exhibits moderate binding to the CRTH2/DP2 receptor compared to PGD2 and essentially no activity at the DP1 receptor.

HY-10418R

AH 6809 (Standard)	Reference Standards Prostaglandin Receptor	Inflammation/Immunology Endocrinology
AH 6809 (Standard) is the analytical standard of AH 6809. This product is intended for research and analytical applications. AH 6809 is an antagonist of EP and DP receptor, with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively. AH 6809 has a Ki of 350 nM for mouse EP2 receptor .

HY-13214

AM-461	Prostaglandin Receptor	Inflammation/Immunology
AM-461 is a *DP2* receptor (Prostaglandin Receptor) antagonist. AM-461 can be used for the researches of inflammation and immunology, such as asthma .

HY-19499

AMG-009	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
AMG-009 is a potent antagonist of prostaglandin D2, with IC₅₀ of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.

HY-106206

AL-6598	Prostaglandin Receptor	Cardiovascular Disease
AL-6598 is a partial agonist of the DP and EP prostaglandin receptors. AL-6598 reduces intraocular pressure and is used in glaucoma research .

HY-P3213

Dp[Tyr(methyl)2,Arg8]-Vasopressin	Vasopressin Receptor	Metabolic Disease
Dp[Tyr(methyl)2,Arg8]-Vasopressin is a non-selective peptide arginine vasopressin Vlb receptor antagonist .

HY-116890

CRTh2 antagonist 4	Prostaglandin Receptor	Inflammation/Immunology
CRTh2 antagonist 4 (compound 58) is an inhibitor (IC₅₀: 212 nM) of TH2 lymphocyte (CRTH2 or *DP2) receptor* with high binding affinity (Ki= 37 nM). CRTh2 antagonist 4 can be used in the study of severe allergic diseases .

HY-118190

AL 8810 methyl ester	Prostaglandin Receptor	Endocrinology
AL 8810 methyl ester is a prostaglandin F(2α) analog and a prostaglandin F(2α) receptor agonist. Can competitively antagonize the effects of the FP receptor agonist Fluprostenol (HY-108560). AL 8810 methyl ester has no significant potency against TP, DP, EP(2), EP(4) receptor subtypes in cell lines .

HY-135208

tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate	Drug Intermediate	Neurological Disease
tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate is an intermediate used in the synthesis of potent DP2 receptor antagonists based on a novel spiro-indolinone compound .

HY-116028

15-deoxy-Δ12,14-Prostaglandin D2 15-Deoxy-Δ12,14-PGD2	Endogenous Metabolite Prostaglandin Receptor PPAR Src	Cardiovascular Disease
15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2), a metabolite of PGD2 (HY-101988), is an agonist of *prostaglandin receptor* 2 (DP2). 15-deoxy-Δ12,14-Prostaglandin D2 binds to DP2 (Ki=50 nM) and induces eosinophil activation (EC₅₀*=8 nM). 15-deoxy-Δ12,14-Prostaglandin D2 also stimulates the recruitment of steroid receptor* coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), inducing PPARγ-mediated transcription. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is cytotoxic to L1210 murine leukemia cells (IC₅₀=0.3 μg/ml) and inhibits ADP-induced platelet aggregation (IC₅₀=320 ng/mL).

HY-118830S1

13,14-Dihydro-15-keto prostaglandin D2-d9 DK-PGD2-d₉; 15-Oxo-13,14-dihydro-PGD2-d₉; 13,14-Dihydro-15-keto-PGD2-d₉	Isotope-Labeled Compounds Prostaglandin Receptor	Endocrinology
13,14-Dihydro-15-keto prostaglandin D2-d₉ (DK-PGD2-d₉) is deuterium labeled 13,14-Dihydro-15-keto prostaglandin D2. 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the *DP2* receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .

HY-182473

AL-6556	Prostaglandin Receptor	Neurological Disease
AL-6556 is a full agonist of the DP receptor and a partial agonist of the EP2 receptor. AL-6556 has an EC₅₀ of 799 nM for bovine DP, a K_i of 3200 nM for human DP, and an EC₅₀ of 1180 nM for human EP2, with selectivity over EP3, FP, IP, TP and 19 non-prostaglandin receptors. AL-6556 stimulates cAMP production via receptor activation and reduces intraocular pressure through aqueous humor inflow and outflow mechanisms. AL-6556 can be used in research related to ocular hypertension and glaucoma .

HY-116028S1

15-deoxy-Δ12,14-Prostaglandin D2-d4 15-Deoxy-Δ12,14-PGD2-d₄	Isotope-Labeled Compounds Endogenous Metabolite Prostaglandin Receptor PPAR Src	Inflammation/Immunology Cancer
15-Deoxy-Δ12,14-Prostaglandin D2-d₄ (15-Deoxy-Δ12,14-PGD2-d₄) is the deuterium labeled 15-deoxy-Δ12,14-Prostaglandin D2. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is a metabolite of prostaglandin D₂ (PGD₂) (HY-101988), which can undergo further dehydration metabolism to 15-deoxy-Δ12,14-PGJ₂. 15-deoxy-Δ12,14-Prostaglandin D2 is a highly selective agonist for DP2 receptor and PPARγ. 15-deoxy-Δ12,14-Prostaglandin D2 causes morphological changes in eosinophils and migration of type II innate lymphoid cells (ILC2). 15-deoxy-Δ12,14-Prostaglandin D2 has a growth inhibitory effect on prostate cancer cells expressing PPARγ, induces cell cycle arrest and promotes apoptosis. 15-deoxy-Δ12,14-Prostaglandin D2 can be used in related research on asthma and prostate cancer.

HY-101987A

(Rac)-BW 245C	Drug Isomer Prostaglandin Receptor	Cardiovascular Disease Neurological Disease
(Rac)-BW 245C is a Rac isomer of BW 245C (HY-101987 ). BW 245C is a prostanoid DP-receptor (DP1) agonist, can be used to study stroke .

HY-101987R

BW 245C (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Endocrinology
BW 245C (Standard) is the analytical standard of BW 245C (HY-101987). This product is intended for research and analytical applications. BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.

HY-13213A

AM211 sodium	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
AM211 sodium is a potent, selective and orally bioavailable prostaglandin D2 (PGD2) receptor type 2 (DP2) antagonist, with IC₅₀s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat DP2, respectively.

HY-16768R

Fevipiprant (Standard) QAW039 (Standard); NVP-QAW039 (Standard)	Prostaglandin Receptor Reference Standards	Cardiovascular Disease
Fevipiprant (Standard) is the analytical standard of Fevipiprant. This product is intended for research and analytical applications. Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an Kd value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma .

HY-116811

AZ-11665362	Prostaglandin Receptor Serotonin Transporter Aldose Reductase Cytochrome P450	Inflammation/Immunology
AZ-11665362 is a CRTh2 (DP2) receptor antagonist with an IC₅₀ of 2.6 nM. AZ-11665362 shows weak activity against aldose reductase, serotonin transporter, CYP 2C19, and CYP 2C9. AZ-11665362 lacks measurable inhibitory activity against COX-1 and COX-2. AZ-11665362 can be used for the research of asthma, and other inflammatory diseases .

HY-183037

AGN 225660	Prostaglandin Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
AGN 225660 is a multi-prostanoid receptor antagonist with human IC₅₀ values of 70, 70, 5, 220 and 180 nM for EP1, EP4, TP, *DP1, FP. AGN 225660 inhibits secretion of RANTES, IL-8, MCP-1, IL-12p70, and IL-23*. AGN 225660 exhibits good ocular bioavailability and reduces ocular inflammation linked to phacoemulsification surgery and uveitis .

HY-160844

CT-133	Prostaglandin Receptor TNF Receptor Interleukin Related	Inflammation/Immunology
CT-133 is a selective and potent CRTH2 Receptor antagonist, with a K_i value of 2.2 nM. The K_i value for the DP1 receptor is greater than 3800 nM. CT-133 inhibits neutrophil migration induced by PGD2 (HY-101988). CT-133 significantly alleviates lung inflammation and improves lung function impairment in a mouse model of acute lung injury (ALI) induced by cigarette smoke. CT-133 effectively inhibits the excessive expression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and chemokines (KC), and reverses the inhibition of the anti-inflammatory factor IL-10. CT-133 can be used for the study of ALI .

製品番号	製品名	Type

HY-172820

Trastuzumab envedotin

DP303c

蛍光色素

Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

製品番号	製品名	Category	Target	構造式

HY-113366

Prostaglandin J2 PGJ2	Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

製品番号	製品名	構造式

HY-118830S1

13,14-Dihydro-15-keto prostaglandin D2-d9

13,14-Dihydro-15-keto prostaglandin D2-d₉ (DK-PGD2-d₉) is deuterium labeled 13,14-Dihydro-15-keto prostaglandin D2. 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .

HY-116028S1

15-deoxy-Δ12,14-Prostaglandin D2-d4

15-Deoxy-Δ12,14-Prostaglandin D2-d₄ (15-Deoxy-Δ12,14-PGD2-d₄) is the deuterium labeled 15-deoxy-Δ12,14-Prostaglandin D2. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is a metabolite of prostaglandin D₂ (PGD₂) (HY-101988), which can undergo further dehydration metabolism to 15-deoxy-Δ12,14-PGJ₂. 15-deoxy-Δ12,14-Prostaglandin D2 is a highly selective agonist for DP2 receptor and PPARγ. 15-deoxy-Δ12,14-Prostaglandin D2 causes morphological changes in eosinophils and migration of type II innate lymphoid cells (ILC2). 15-deoxy-Δ12,14-Prostaglandin D2 has a growth inhibitory effect on prostate cancer cells expressing PPARγ, induces cell cycle arrest and promotes apoptosis. 15-deoxy-Δ12,14-Prostaglandin D2 can be used in related research on asthma and prostate cancer.

HY-118830S

13,14-Dihydro-15-keto prostaglandin D2-d4

13,14-Dihydro-15-keto prostaglandin D2-d₄ (DK-PGD2-d₄) is deuterium labeled 13,14-Dihydro-15-keto prostaglandin D2. 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: